439 results on '"Strober, Bruce E."'
Search Results
2. Brodalumab: 5-Year US Pharmacovigilance Report
3. Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)
4. Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
5. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
6. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry
7. Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR
8. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
9. Hidradenitis suppurativa: Current and emerging treatments
10. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis
11. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
12. Orismilast in moderate-to-severe psoriasis:Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)
13. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy
14. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
15. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
16. Clinical Goals and Barriers to Effective Psoriasis Care
17. Psoriasis and Down syndrome: A report of three cases and a potential pathophysiologic link
18. Disseminated superficial porokeratosis
19. 41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials
20. Acrodermatitis continua
21. Erythrokeratodermia variabilis
22. Pachyonychia congenita, type II
23. Generalized morphea
24. Tinea Capitis
25. Lupus panniculitis (lupus profundus)
26. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
27. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
28. P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis
29. Current biologic therapies (including IL-17) and monitoring guidelines
30. Item-Level Psychometric Properties for a New Patient-Reported Psoriasis Symptom Diary
31. 51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry
32. How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials
33. A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
34. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
35. Similar Names for Similar Biologics
36. Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series
37. Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation
38. Laboratory monitoring requirements during mycophenolate mofetil therapy for dermatologic conditions: A single-institution retrospective chart review
39. The Treatment of Moderate-to-Severe Psoriasis: Prescreening and Monitoring Psoriatic Patients on Biologics
40. Getting personal about skin: Realizing precision medicine in dermatology
41. 27374 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial
42. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1
43. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2
44. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
45. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
46. Methotrexate-Induced Liver Toxicity: Replacing the Liver Biopsy
47. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument
48. 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
49. 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
50. Off-Label Dermatologic Uses of Anti-TNF-a Therapies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.